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Abstract Effects of oral alprazolam (0.5 and 1 mg) and
lorazepam (2 mg) on sympathetic adrenomedullary
activity and sedation were studied during supine rest,
mental load (Color Word Test, CWT) and active stand-
ing (OCT), in 12 male volunteers in a randomized
double-blind placebo-controlled cross-over design.
Compared to placebo, alprazolam significantly
increased subjective sedation, reduced plasma adrena-
line and noradrenaline concentrations and mean blood
pressure (MBP) during supine rest, and attenuated
plasma adrenaline responses during the CWT and
the OCT; these effects during the CWT and OCT
appeared to be dose-dependent. In comparison with
lorazepam (2 mg), alprazolam (1 mg) showed reduced
MBP levels during supine rest, whereas lorazepam
showed a higher heart rate level during supine rest, a
reduced plasma noradrenaline response to the
OCT and a performance deterioration to the CWT.
There were no differences between alprazolam 
(1 mg) and lorazepam regarding subjective sedation.
Although the benzodiazepines were similar regarding
their increase of sedation, alprazolam and loraze-
pam induced differential effects on sympathetic
adrenomedullary activity during rest and stress,
whereby suppression of adrenomedullary activity may
be specific for alprazolam.
Key words Benzodiazepines · Adrenaline ·
Noradrenaline · Blood pressure · Heart rate ·
Sedation · Mental stress · Physical stress
Introduction
Activation of the sympathetic adrenomedullary
system is of great importance for the physiological
adaptation to a range of mental and physical situa-
tions. During stressful situations, activation of the sym-
pathetic nervous system may be accompanied by
changes in subjective mood such as anxiety, irritabil-
ity or dysforia (Lader and Bruce 1986). Moreover,
chronic increased sympathetic activity due to stressful
situations may be relevant for the pathogenesis of anx-
iety states and cardiovascular diseases such as hyper-
tension (Brown and MacQuin 1981; Charney et al.
1984).
Treatment of anxiety symptoms in patients with
cardiovascular dysfunction often includes benzodi-
azepines. Because suppression of stress-induced
sympathetic adrenomedullary activation may be desir-
able in patients with stress related cardiovascular dis-
orders, a benzodiazepine with such properties is of
great interest. Alprazolam is a benzodiazepine simi-
lar to other benzodiazepines in its anxiolytic proper-
ties (Dawson et al. 1984), but different in other
respects. In the rat, it antagonizes stress-induced
increases in adrenaline and noradrenaline concentra-
tions (Vogel et al. 1984). Alprazolam also protects
against stress-induced cardiac damage in hamsters
with cardiomyopathy (Tapp et al. 1989) and in rats
treated with isoproterenol (Berkowitz et al. 1988).
Some of these effects may be related to stimulation
of a2-receptors by alprazolam, although it does not
seem to bind directly to these receptors (Rick-Brand
and Müller 1988). Unlike diazepam, alprazolam
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antagonizes the reserpine-induced increase in b-recep-
tors, which may be related to the antidepressant effects
of alprazolam (Sethy and Hodges 1982). In humans,
alprazolam may suppress adrenergic as well as nora-
drenergic function, although conflicting data exist
(Stratton and Halter 1985; Risby et al. 1989; Linnoila
et al. 1990; McLeod et al. 1990; Breier et al. 1992;
Osman et al. 1993). Studies in humans have also
suggested that there are differences between benzodi-
azepines with respect to sedative properties: alprazo-
lam may induce less sedation in comparison with
clinically equivalent doses of other benzodiazepines
(Dawson et al. 1984; Subhan et al. 1986; Greenblatt
et al. 1988).
In a previous study we have shown the usefulness of
the Stroop Color Word Test (CWT) as a psychologi-
cal performance task that is capable of inducing
psychic distress and sympathetic adrenomedullary
activation as shown by increased cardiovascular activ-
ity and plasma catecholamine secretion (Tulen et al.
1989). In a sequel study, we have shown that lorazepam
had no specific effects on these responses to the CWT
(Tulen et al. 1991, 1994).
The present study aimed to investigate whether oral
administration of alprazolam influences catecholamin-
ergic and cardiovascular activity during periods of rest
and mental load (CWT), different from lorazepam and
in comparison with placebo, in healthy volunteers. The
responses to mental load were compared with responses
to a physical task that is known to increase sympa-
thetic nervous system activity (orthostatic challenge).
Special attention was paid to plasma adrenaline con-
centrations, because several studies suggest that alpra-
zolam specifically attenuates adrenomedullary activity
(Stratton and Halter 1985; Breier et al. 1992). This has
so far not been studied during mental challenge tasks
in humans. In addition, the sedative properties of alpra-
zolam were studied.
Because effects on catecholaminergic and cardio-
vascular responses and subjective sedation may be dose
dependent, the effects of a relatively high (1 mg) and
a moderate (0.5 mg) oral dose of alprazolam were
evaluated and compared in a double-blind placebo-
controlled design. Furthermore, responses to the high
dose of alprazolam (1 mg) were compared with
responses to the (approximately) clinically equivalent
oral dose of 2 mg lorazepam, utilizing lorazepam as
an active control for the responses to alprazolam. Both
alprazolam and lorazepam are reported to be moder-
ately rapidly absorbed, with peak plasma concentra-
tions occurring between 0.7 and 2.1 h after oral
administration, and both benzodiazepines can be
regarded as intermediate half-life benzodiazepines
(elimination half-life of lorazepam: 12–13 h; alprazo-
lam: 9–19 h), whereas no active metabolites of
interest are formed (Kyriakopoulos et al. 1978;
Ellinwood et al. 1985;  Higgitt et al. 1988; Huybrechts
1991).
Materials and methods
Subjects
Twelve healthy male volunteers with a mean (±SD) age of 22 (±2)
years participated in a double-blind, randomized, placebo-con-
trolled, cross-over study. Only male subjects were included because
the phase of the menstrual cycle in females can have an effect on
plasma catecholamine concentrations and autonomic nervous sys-
tem responses to stress. The subjects underwent medical and psy-
chiatric screening prior to inclusion into the study. All subjects had
negative personal and family histories for psychiatric illness and
substance abuse and had been medication free for at least 2 months
prior to the study. The subjects were instructed to keep a regular
sleep-wake pattern and to avoid physical or psychic exertions start-
ing 3 days before the experimental sessions. During these days, alco-
hol consumption had to be limited to a maximum of one
consumption per day. The subjects did not smoke more than five
cigarettes per day. The study was approved by the Medical Ethical
Review Committee of the University Hospital Rotterdam Dijkzigt.
All subjects gave written consent prior to inclusion into the study.
Procedures
All subjects received, in a randomized and double blind order, either
an oral dose of 0.5 mg alprazolam (ALP0.5), 1 mg alprazolam
(ALP1), 2 mg lorazepam (LOR), or a placebo (PLA), on 4 different
days which were separated by at least 5 days. All medications con-
sisted of the commercially available oral dosage form, which was
placed in an opaque capsule with a rapid disintegration rate. The
four medications looked identical.
On the experimental day, the subjects had breakfast at home;
coffee and smoking were not allowed before or during the session.
Each session lasted from 8.15 a.m. until 12.15 a.m. At 8.15 a.m.,
the subjects received the oral dose of ALP0.5, ALP1, LOR or PLA;
30 min hereafter the experiment started. Subjects were studied dur-
ing three periods of supine rest (15 min each) with 60 min between
the periods. Between first and second supine periods, the subjects
performed two tasks: the Color Word Test (CWT) as a mental effort
task and the Orthostatic Challenge Test (OCT) as a physical task.
Following the first supine rest period, the volunteers were subjected
to the CWT (10 min) after a stabilization period in the sitting posi-
tion (10 min). Details of the CWT have been described before (Tulen
et al. 1989, 1991). Hereafter, the OCT was performed: the subjects
stood for 10 min at ease in the upright position (active standing).
After the second supine rest period, the test procedures were
repeated in reversed order. In this paper, we will report the effects
of alprazolam and lorazepam on the three consecutive periods of
supine rest, as well as the effects of the drugs on the responses to
the first CWT and OCT.
Measurements and analyses
Forty-five minutes prior to the start of the measurements, a catheter
(Venflon, 18G, Viggo AB, Helsenborg, Sweden) was inserted into
an antecubital vein of the non-dominant forearm, for serial blood
sampling. For determination of the plasma concentrations of
ALP0.5, ALP1 and LOR, blood (10 ml) was collected after each
resting period in EDTA tubes. Blood was centrifuged (10 min,
4000 g) and plasma was stored at [70°C until it was assayed.
Alprazolam and lorazepam plasma concentrations were assayed by
means of high performance liquid chromatography with UV detec-
tion, after isolation from plasma by an extraction with
heptane: isoamylalcohol (90:10). For determination of plasma
adrenaline and noradrenaline concentrations, blood (10 ml) had
been collected in chilled heparinized tubes containing 12 mg
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gluthathione, after each supine or sitting rest period, after 5 min
during performance of the CWT and after 10 min of standing. The
blood samples were centrifuged at 4°C (15 min, 3000 g); plasma
was subsequently stored at [70°C until assay. Catecholamines were
assayed by means of high performance liquid chromatography with
fluorimetric detection after isolation from plasma by a specific liq-
uid-liquid extraction method and derivatization with the selective
fluorogenic agent 1,2-diphenylethylenediamine (van der Hoorn
et al. 1989).
ECG and blood pressure were recorded continuously during the
session on a multichannel FM-type analogue recorder (Racal Store
14 DS, Sarasota, Flo. USA). Signals were on-line digitized at a sam-
ple frequency of 102.4 Hz on a personal computer (Dell optiplex
466/L) connected to an Analogue/Digital converter (Advantech PC-
LabCard model PCL-718). The ECG was derived using a precordial
lead, amplified by means of a polygraph (Nihon Kohden, Tokyo,
Japan). R-R intervals in the ECG were detected with an accuracy of
10 ms and transposed to heart rate (HR) series. Blood pressure was
recorded using a servo-plethysmomanometer for continuous non-
invasive measurements of finger arterial blood pressure, employing
the volume clamp technique of Penaz (Penaz et al. 1976; Settels and
Wesseling 1985) (Finapres 2300 NIBP monitor, Ohmeda, Englewood,
Col. USA). Mean (MBP) blood pressure was defined as the mean of
the individual blood pressure values between two consecutive R-
waves of the ECG. Cardiovascular data were analyzed per 5-min
period for the rest and OCT situations, and per 2.5 min for the CWT.
Responses to the CWT and active standing were defined as changes
in absolute levels. For the CWT, differences were computed between
the stabilized part of the test (last 2.5 min) and the preceding 5-min
period of sitting. For the OCT, the response was defined as the
difference between the stabilized part of the active standing (last
5 min) and the preceding period of supine rest (last 5 min).
Changes in sleepiness were assessed by means of the Dutch trans-
lation of the Stanford Sleepiness Scale (Hoddes et al. 1973). Changes
in subjective mood were assessed by means of a shortened version
of the vigor and fatigue subscales of the Profile Of Mood States
(POMS) (McNair et al. 1978; validated Dutch version: Wald and
Mellenbergh 1990) and a shortened state-version of the State-Trait
Anxiety Inventory (STAI) (validated Dutch version: van der Ploeg
et al. 1980; shortened version: Knippenberg et al. 1990). Sleepiness,
mood and anxiety scores were obtained after each rest period. In
this report, only sleepiness data will be presented.
Statistical analysis
Statistical analyses were performed using SPSS for Windows
Release 6.0 (SPSS Inc.). Multivariate analyses of variance
(MANOVA) for repeated measurements were performed to explore
the effects of ALP0.5 and ALP1, in comparison to PLA and LOR,
on catecholaminergic, cardiovascular and psychological parameters
(n = 12 unless otherwise specified). Two primary hypotheses were
tested:
1. H0: the catecholaminergic, cardiovascular and sleepiness vari-
ables are not influenced by alprazolam, as compared to placebo.
H1: Alprazolam affects the catecholaminergic, cardiovascular
and sleepiness variables differently then placebo.
2. H0: the catecholaminergic, cardiovascular and sleepiness vari-
ables are not differently affected by alprazolam (1 mg), as com-
pared to lorazepam (2 mg).
H1: Alprazolam (1 mg) affects the catecholaminergic, cardio-
vascular and sleepiness variables differently, as compared to
lorazepam (2 mg).
Supine rest
To test hypothesis 1, two-factor MANOVAs for repeated mea-
surements with Helmert contrasts were performed: factor DRUG
(PLA, ALP0.5 and ALP1) and factor TIME (three supine rest peri-
ods). The averaged tests of significance were used to explore drug,
time and interaction effects, when Mauchly’s test of sphericity
revealed no deviations from the symmetry assumptions. The Huyn-
Feldt epsilon was used to adjust the degrees of freedom for the
averaged results. To test hypothesis 2, the same strategy was used
as described above, but with the factors: Drug (ALP1 and LOR)
and TIME (three supine rest periods).
CWT and OCT
To test hypothesis 1, the same strategy was used as described above,
but without the factor Time. To test hypothesis 2, paired t-tests
were performed. In all cases, a P-value of <0.05 was considered
significant.
Results
Benzodiazepine concentrations
The maximum plasma concentrations for ALP0.5
(8.1 ± 2.0 ng/ml), ALP1 (15.3 ± 3.4 ng/ml) and LOR
(13.6 ± 2.1 ng/ml) were reached approximately 2 h
(ALP0.5 and ALP1) and 1.5 h (LOR) after adminis-
tration (Fig. 1). The individual peak concentrations,
ranging from 6.7 to 13.3 ng/ml for ALP0.5, from 12.8
to 21.6 ng/ml for ALP1, and from 10.9 to 20.5 ng/ml
for LOR, were reached between 0.8 and 3 h after
administration. The changes over time with the
different drugs were not significantly different.
Supine rest (Tables 1, 3)
Plasma catecholamines
Plasma adrenaline concentrations (Fig. 2) were reduced
after administration of ALP0.5 and ALP1, as shown
by a trend drug effect (P = 0.06). However, no dose
effect was found and plasma adrenaline concentrations
after ALP1 and LOR administration were not signifi-
cantly different. Plasma noradrenaline concentrations
were significantly altered (P < 0.05); inspection of the
plasma concentrations showed a reduction of plasma
noradrenaline concentrations after ALP1 administra-
tion, but not after ALP0.5 administration (Fig. 2).
During all sessions, plasma adrenaline and noradrena-
line levels showed a time-dependent increase (P < 0.01).
Blood pressure
The mean blood pressure (MBP) was significantly
reduced after the administration of ALP0.5 and ALP1
(P < 0.05) (Fig. 2). No differences were found between
the effect of ALP0.5 and ALP1. MBP after ALP1
administration was significantly reduced in compari-
son with MBP after LOR administration (P < 0.05).
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Supine rest
Placebo Alprazolam 0.5 mg Alprazolam 1 mg Lorazepam 2 mg
S1 S2 S3 S1 S2 S3 S1 S2 S3 S1 S2 S3
Adr (pg/ml) 10.4 8.8 13.0 6.5 7.1 7.7 6.5 6.8 9.0 6.6 10.4 12.3
(5.2) (3.4) (6.4) (4.7) (3.7) (4.5) (5.4) (4.4) (7.3) (3.3) (6.2) (7.4)
Noradr (pg/ml) 159.0 162.8 184.8 149.8 174.3 216.3 125.1 146.5 166.7 142.8 166.9 177.2
(43.9) (46.6) (62.0) (37.7) (76.0) (123.1) (46.8) (66.1) (64.0) (52.1) (66.6) (61.0)
HR (bpm) 63.3 61.2 59.2 61.7 59.4 56.2 64.5 61.2 57.8 62.0 62.4 60.9
(8.3) (7.0) (6.1) (8.3) (7.6) (5.3) (10.9) (10.1) (7.7) (9.3) (10.4) (9.2)
MBP (mm Hg) 76.6 79.1 81.6 71.5 75.0 79.0 71.9 75.6 79.9 75.2 80.6 85.8
(9.8) (5.4) (7.8) (9.1) (7.8) (8.3) (9.0) (7.9) (10.0) (9.9) (10.6) (10.6)
SSS 2.1 2.3 1.8 2.5 3.3 2.7 2.9 3.5 3.0 2.8 3.6 3.2
(0.9) (1.3) (0.9) (1.3) (1.6) (1.1) (1.1) (1.8) (1.0) (1.0) (1.4) (1.5)
Fig. 1 Mean (+SD) plasma
benzodiazepine concentrations
after oral administration of
alprazolam (0.5 mg and 1 mg)
and lorazepam (2 mg), during
a 3-h period after
administration
CWT OCT
PLA ALP0.5 ALP1 LOR PLA ALP0.5 ALP1 LOR
Adr (pg/ml) 10.5 8.6 3.7 8.1 15.6 8.6 5.8 18.8
(11.6) (7.1) (5.2) (13.1) (15.6) (6.0) (5.8) (26.3)
Noradr (pg/ml) [8.9 [6.7 5.5 2.1 259.4 253.6 294.6 220.1
(43.7) (36.5) (54.8) (39.1) (88.5) (75.9) (138.7) (71.5)
HR (bpm) 7.7 5.6 9.6 11.3 25.0 26.6 27.0 26.3
(7.4) (4.8) (6.6) (7.4) (7.6) (11.9) (8.8) (8.3)
MBP (mmHg) 13.8 9.8 12.8 10.8 12.0 11.8 13.7 15.2
(9.3) (4.7) (6.6) (7.0) (5.8) (3.6) (6.9) (8.0)
#ERR 2.4 6.2 6.0 18.1
(3.6) (15.4) (6.4) (14.6)
Table 2 The mean (SD)
response of plasma
adrenaline, plasma
noradrenaline, heart rate, and
mean blood pressure during
the CWT and OCT, as well
as the number of errors to
the CWT, after placebo,
alprazolam (0.5 and 1 mg)
and lorazepam (2 mg)
administration
Table 1 The mean (SD) plasma adrenaline concentrations (Adr),
plasma noradrenaline concentrations (Noradr), heart rate (HR),
mean blood pressure (MBP) and scores on the Stanford Sleepiness
scale (SSS) during the three supine rest periods (S1,S2,S3) after
placebo, alprazolam (0.5 and 1 mg) and lorazepam (2 mg) admin-
istration
During all sessions, the MBP showed a significant
increase over time.
Heart rate
HR was not differently affected by ALP0.5 or ALP1,
in comparison with placebo. However, ALP1 and LOR
affected the HR differently, as shown by a drug-by-time
interaction effect (P < 0.01): HR after LOR adminis-
tration showed a slower reduction over time, in com-
parison with ALP1. HR decreased over time during all
sessions (P < 0.01).
Sleepiness
Sleepiness increased between the first and second supine
period and decreased between the second and third
period. In comparison with PLA administration, sleepi-
ness increased significantly after administration of
ALP0.5 and ALP1 (Fig. 2) (P < 0.01), whereas no
differences were found between the ALP0.5 and ALP1
sessions and the ALP1 and LOR sessions.
Mental load (CWT) (Tables 2, 3)
Performance to the CWT
The number of errors made during performance of the
CWT was not significantly influenced after ALP0.5 and
ALP1 administration; the number of errors after LOR
administration was significantly increased in compari-
son to the number of errors after ALP1 administration
(P < 0.05) (Fig. 3).
Plasma catecholamines
After PLA administration, plasma adrenaline 
concentrations increased with 10.5 ± 11.6 (pg/ml) 
during performance of the CWT (Fig. 3). CWT
responses of plasma adrenaline concentrations after
ALP0.5 and ALP1 administration were reduced, as
shown by a trend multivariate effect (P = 0.06). This
reduction by ALP was less during the ALP0.5 session
than during the ALP1 session. No significant differences
were found regarding plasma adrenaline response mag-
nitudes between the ALP1 and LOR sessions. Plasma
noradrenaline concentration during performance of the
CWT was not influenced by either benzodiazepine.
Blood pressure
After PLA administration, MBP increased with
13.8 ± 9.3 mmHg during performance of the CWT.
MBP response magnitudes were not affected by either
drug or dose, in comparison with PLA administration.
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Heart rate
The mean HR response to the CWT was 7.7 ± 7.4 bpm
during the PLA session. HR response after ALP0.5 and
ALP1 administration was not significantly different from
PLA administration, and the HR response to the CWT
after ALP1 administration was not significantly different
from HR response after LOR administration.
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Fig. 2 Mean (+SD) plasma
adrenaline concentrations,
plasma noradrenaline
concentrations, mean blood
pressure and sleepiness scores
during the three consecutive
supine rest periods (1,2,3), for
the PLA, ALP0.5, ALP1 and
LOR sessions separately
Fig. 3 Mean (+SD) plasma
adrenaline response and the
performance to the CWT, for
the PLA, ALP0.5, ALP1 and
LOR sessions separately
Fig. 4 Mean (+SD) plasma
adrenaline and noradrenaline
response to the OCT, for the
PLA, ALP0.5, ALP1 and
LOR sessions separately
Active standing (OCT) (Tables 2,3)
Plasma catecholamines
During the PLA session, the plasma adrenaline con-
centrations increased during performance of the OCT
with 15.6 ± 15.6 (pg/ml); the plasma noradrenaline
concentrations increased with 259 ± 88 (pg/ml). 
The adrenaline response (Fig. 4) to the OCT was
significantly reduced during the ALP0.5 and ALP1 ses-
sions, as compared to the PLAC session (P < 0.05).
After administration of ALP1, the OCT response was
less than after administration of ALP0.5. The adrena-
line response to the OCT after ALP1 administration
was not significantly different as compared to LOR.
The noradrenaline response to the OCT was not infl-
uenced by ALP0.5 and ALP1, but the noradrenaline
response after LOR administration was significantly
reduced in comparison with ALP1 (P < 0.05) (Fig. 4).
Blood pressure
After PLA administration, MBP increased with
12.0 ± 5.8 mmHg during performance of the OCT.
Administration of ALP0.5, ALP1 or LOR did not alter
the MBP response to the OCT. 
Heart rate
The HR increased with 25.0 ± 7.6 bpm during the OCT
of the PLA session. HR response was not altered by
either drug or dose.
Discussion
The aim of this study was to evaluate the effects of
alprazolam on sympathetic nervous system activity
during rest, mental load, and active standing. Two oral
dosages of alprazolam (0.5 mg and 1 mg) were com-
pared to placebo and lorazepam (2 mg). Compared
with placebo administration, alprazolam induced a
trend towards a reduction of plasma adrenaline con-
centrations during supine rest and mental load, and
significantly suppressed adrenaline concentrations dur-
ing orthostatic challenge; the effects during the CWT
and the OCT appeared to be dose-dependent. In addi-
tion, alprazolam significantly suppressed MBP and
plasma noradrenaline concentrations, but only during
supine rest. At both dose levels, alprazolam signifi-
cantly increased subjective sedation. When comparing
responses to alprazolam (1 mg) and lorazepam (2 mg),
alprazolam showed reduced MBP levels during supine
rest, whereas lorazepam showed a higher HR level
during supine rest, a reduced plasma noradrenaline
response to the OCT and a performance deterioration
to the CWT. There were no differences between alprazo-
lam (1 mg) and lorazepam (2 mg) regarding subjective
sedation.
Alprazolam versus Placebo
Plasma catecholamines
As indicators of sympathetic nervous system activity,
plasma adrenaline (adrenomedullary activity) and
noradrenaline (sympathoneural activity) concentra-
tions were used. ALP tended to reduce the plasma
adrenaline concentrations during supine rest, attenu-
ated the adrenaline response to active standing, and
tended to decrease the adrenaline response to mental
load. These data indicate a suppressing effect of ALP
on the adrenomedullary system, as well as a dose
dependent attenuation of the stress induced activation.
Although these effects were obtained under standard-
ized conditions, the effects were nevertheless small.
However, these effects of ALP on the plasma adrena-
line concentrations are consistent with the findings
reported by Stratton and Halter (1985). They described
reduced plasma adrenaline concentrations during
supine rest and reduced plasma adrenaline responses
during physical stress (treadmill exercise) after admin-
istration of ALP (0.5 mg 3 times daily, orally, for 3
days). McLeod et al. (1990) also reported reduced
adrenaline concentrations after ALP administration
(0.5 mg, 1–12 times daily, orally, for 6 weeks) during a
resting period in the sitting position in patients with
generalized anxiety disorder. In addition, Breier et al.
(1992) described an attenuation of the plasma adrena-
line response to glucoprivic stress (2-deoxyglucose
administration) by ALP (1.5 mg, orally). Our data are
the first to show that alprazolam also attenuates the
relatively small adrenomedullary responses during
mental load and active standing.
In our study, plasma noradrenaline concentrations
during supine rest were reduced by the higher dose of
ALP (1 mg), but the responses to the CWT and OCT
were not affected. The reduction of plasma noradrena-
line concentrations after ALP administration during
supine rest is consistent with the findings reported by
McLeod et al. (1990) and Risby et al. (1989). Risby
et al. described reduced plasma noradrenaline concen-
trations during supine rest after intravenous adminis-
tration of ALP (0.02 mg/kg). However, others found
no effect of ALP on plasma noradrenaline concentra-
tions during supine rest [Stratton and Halter 1985;
Linnoila et al. 1990 (alprazolam: 0.5 mg or 2 mg,
orally)]. In contrast to our results, Stratton and Halter
(1985) described a reduction of the noradrenaline
response by ALP during the performance of a tread-
mill exercise, but Breier et al. (1992) found no effect of
ALP on the response to glucoprivic stress (2-deoxyglu-
cose administration).
27
The inconsistent findings about the influence of ALP
on plasma noradrenaline concentrations can perhaps
be explained by methodological differences. During
rest, different methods were used with regard to pos-
ture (supine and sitting) and drug administration (oral
and intravenous; single and multiple administration).
Also, different stressors were used (mental, physical,
exercise, and metabolic stress). Furthermore, interpre-
tation of concentrations of venous noradrenaline is
hampered by the fact that these concentrations are
influenced by local sympathetic nervous system activ-
ity at the site of sample collection and concentrations
are also highly dependent on the rate at which nora-
drenaline is removed from the circulation and not only
its release into plasma (Floras et al. 1986; Esler et al.
1988; Tulen 1993). This may explain some of the
differential effects of mental stressors versus physical
stressors and exercise.
Cardiovascular effects
ALP reduced the MBP during supine rest, but did not
influence the stress induced MBP responses. Reduced
BP after ALP administration is consistent with other
reports in the literature [Risby et al. 1989; Linnoila
et al. 1990; Rohrer et al. 1994 (alprazolam: 0.5 mg);
McLeod et al. 1990], although some studies observed
no effect [Stratton and Halter 1985; Osman et al. 1993
(alprazolam: 0.003, 0.007, 0.02 mg/kg, intravenously)].
The unaffected MBP responses to mental and physical
stress are in accordance with other studies, where no or
a very modest influence of ALP on the MBP response
was described [Stratton and Halter 1985; Breier et al.
1991; Crowe McCann et al. 1992 (0.5 mg alprazolam,
orally); Rohrer et al. 1994]. HR during supine rest and
the HR response during the mental and physical tasks
were not affected by ALP. Comparable findings for HR
during supine rest have been observed in several stud-
ies (Stratton and Halter 1985; Linnoila et al. 1990;
Osman et al. 1993), although Risby et al. (1989)
described a slight increase. HR, obtained while subjects
were in a sitting position, was reported to decrease after
ALP administration (McLeod et al. 1990; Rohrer et al.
1994). The findings regarding the influences of ALP on
task induced HR increases are divergent. Some studies
describe no influence of ALP administration on the HR
response [Breier et al. 1991 (1.5 mg alprazolam, orally);
Crowe McCann et al. 1992], others observed a reduced
response after ALP (Stratton and Halter 1985; Rohrer
et al. 1994), whereas Linnoila et al. (1990) described a
marginal increase after ALP.
Sedation
Sleepiness increased after both dose levels of alprazo-
lam, although this did not influence performance to
the CWT. Our results are in line with previous studies
reporting increases in subjective sedation after 0.5 or
1.0 mg alprazolam (Dawson et al. 1984; Subhan et al.
1986; Greenblatt et al. 1988; Risby et al. 1989).
Alprazolam (1 mg) versus Lorazepam (2 mg)
Plasma adrenaline concentrations during supine rest
and adrenaline responses to the CWT and OCT were
not differently affected by ALP1 or LOR. However, ver-
sus placebo, the plasma concentrations during supine
rest and the adrenaline responses to the CWT and OCT
indicated a suppressing effect of ALP1 (Figs 2, 3, 4).
These observations make the specificity of a suppress-
ing effect of ALP on the adrenomedullary system ques-
tionable. The mean values of plasma adrenaline
concentrations during CWT and OCT were evidently
lower after ALP1 than after LOR administration
(Tables 1, 2). However, we could not ascertain a
significant difference, possibly due to the relatively high
standard deviations of the adrenaline concentrations
after LOR administration. Further studies are required
to elucidate the reasons for this adrenergic response
variability after LOR administration.
The plasma noradrenaline response during active
standing was not affected by ALP1, but was reduced by
LOR. Collomp et al. (1994) described no changes in
resting plasma noradrenaline concentrations after a dose
of 1.5 mg LOR. In accordance with our previous
findings [Tulen et al. 1991 (intravenous, increasing 0.0,
0.06, 0.13, 0.25 and 0.5 mg; cumulative dose 0.94 mg)],
we observed no effects of LOR on resting catecholamin-
ergic concentrations and responses to the CWT.
The influences of ALP1 and LOR on cardiovascu-
lar variables were also different with regard to the MBP
and the HR levels, but only during supine rest.
Administration of LOR did not affect the MBP dur-
ing supine rest, while ALP1 did suppress the MBP. The
decrease in HR over time was less during the LOR ses-
sion in comparison to the ALP1 session. Both effects
accentuate the suppressing effect of ALP on sympa-
thetic adrenomedullary activity. 
Both ALP1 and LOR equally increased subjective
sedation. Since there were no differences regarding sub-
jective sedation, it is remarkable that performance to
the CWT was deteriorated only after LOR adminis-
tration. Memory impairment and performance deteri-
oration to psychological tasks after a dose of 2 mg
lorazepam are well documented (Subhan et al. 1986;
Greenblatt et al. 1988; Preston et al. 1989; Tulen et al.
1991). Similar effects have been reported after alpra-
zolam (Subhan et al. 1986; Greenblatt et al. 1988;
Linnoila et al. 1990). However, at the present dose lev-
els of alprazolam, subjective sedation was not accom-
panied by performance impairment to the CWT.
The plasma concentrations, peak concentrations and
peak latency of both alprazolam and lorazepam were
28
comparable with previous studies (Kyriakopoulos et al.
1978; Dawson et al. 1984; Greenblatt et al. 1988;
Huybrechts 1991). The plasma concentration curves
after 1 mg ALP and 2 mg LOR were very similar with
respect to the time course during the experiment and
with respect to absolute values. Radioreceptor assays
have shown lorazepam to be about three times as potent
as alprazolam at the central benzodiazepine receptor,
but alprazolam’s free fraction in serum is 2–3 times
higher than lorazepam’s (Arendt et al. 1987). This does
not make it easy to estimate the concentrations and
activity of both compounds at the central benzodi-
azepine receptor when serum concentrations are simi-
lar. Some experiments on memory and psychomotor
functions have shown 0.5 mg alprazolam and 1 mg
lorazepam to be equivalent (Block and Berchou 1984;
Subhan et al. 1986; Kumar et al. 1987). In view of these
data and the parallel time course of the plasma con-
centration curves in this experiment, it would appear
that the differences observed in this study cannot be
ascribed to differences in potency of alprazolam and
lorazepam at the doses investigated.
The mechanisms by which benzodiazepines (BZD)
change sympathetic nervous system activity during rest
or attenuate stress induced sympathoneural and
adrenomedullary activation are not well understood. In
human brains, interaction with specific BZD-receptors
facilitates the inhibitory neurotransmission of the 
neurotransmitter c-aminobutyric acid (GABA). The
GABAa/Bz receptor complex mediates the principal
actions of the BZDs (Breier and Paul 1990). The recep-
tor was found to be localized at multiple brain sites, in
particular the medial hypothalamus, the hippocampus,
cortex, amygdala and brain stem sites such as the locus
coeruleus. GABAa/Bz receptor agonists (such as ALP)
have potent suppressive effects on CRH release, an effect
that is blocked by GABAa/Bz receptor antagonists
(Owens et al. 1989; Kalogeras et al. 1990). CRH plays
a significant role in stress and affective behaviour. Beside
other functions, it enhances autonomic nervous system
activity (Brown et al. 1985; Kreutz et al. 1992). In this
study, both alprazolam and lorazepam affected 
autonomic nervous system activity, although the
effects were small. We observed differential effects
of alprazolam and lorazepam on sympathoneural
and cardiovascular activity, whereby suppression of
adrenomedullary activity occurred only after alp-
razolam administration. The acute effects as observed
in this study need to be further explored in studies
with (sub)chronic drug administration. Neverthe-
less, our data indicate that in the treatment of anxiety
symptoms in patients with cardiovascular disorders,
suppression of adrenomedullary activity by alprazolam
may be an advantage over the use of other benzo-
diazepines.
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